Solid Biosciences Inc. Stock Issued During Period, Value, Conversion of Units
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Solid Biosciences Inc. stock issued during period, value, conversion of units for the quarter ending 2018-12-31 was $0.00.
- Solid Biosciences Inc. stock issued during period, value, conversion of units for the quarter ending 2018-09-30 was $0.00.
- Solid Biosciences Inc. stock issued during period, value, conversion of units for the quarter ending 2018-06-30 was $0.00.
- Solid Biosciences Inc. stock issued during period, value, conversion of units for the quarter ending 2018-03-31 was $124.18M.
- Solid Biosciences Inc. stock issued during period, value, conversion of units for fiscal 2018 was $124.18M.
| Period end | Stock Issued During Period, Value, Conversion of Units 3 month | Stock Issued During Period, Value, Conversion of Units 12 month |
|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $124.18M 10-K · filed 2021-03-15 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | |
| 2018-03-31 | $124.18M 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |